Cargando…
Modeling and Simulation to Support Phase Ib/IIa Dose Selection for WBP216, A Long Half-Life Fully Human Monoclonal Antibody Against Interleukin-6
WBP216 is an innovative IL-6 antibody, presenting high affinity to IL-6 and a long half-life (40–60 days). To optimize the dosage regimen for future clinical trials, pharmacokinetics (PK) and pharmacodynamics (PD) of WBP216 would be firstly characterized in Chinese rheumatoid arthritis (RA) patients...
Autores principales: | Tang, Xiange, Zeng, Xiaofeng, Guan, Xiaoduo, Chen, Rui, Hu, Pei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930490/ https://www.ncbi.nlm.nih.gov/pubmed/33679400 http://dx.doi.org/10.3389/fphar.2021.617265 |
Ejemplares similares
-
Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study
por: Leng, Xiaomei, et al.
Publicado: (2023) -
Biosynthesis of the Pseudomonas aeruginosa common polysaccharide antigen by D-Rhamnosyltransferases WbpX and WbpY
por: Melamed, Jacob, et al.
Publicado: (2022) -
Brain-Gut Interactions in IBS
por: Fichna, Jakub, et al.
Publicado: (2012) -
The emerging roles of WBP2 oncogene in human cancers
por: Tabatabaeian, Hossein, et al.
Publicado: (2020) -
Tanshinone IIA: A Review of its Anticancer Effects
por: Fang, Zhong‐ying, et al.
Publicado: (2021)